Logo image
S2691 SGLT-2 Inhibitors Are Associated With Reduced Hepatic Decompensation and Mortality in Patients With Cirrhosis and Type 2 Diabetes: A Propensity-Matched Real-World Analysis
Abstract   Peer reviewed

S2691 SGLT-2 Inhibitors Are Associated With Reduced Hepatic Decompensation and Mortality in Patients With Cirrhosis and Type 2 Diabetes: A Propensity-Matched Real-World Analysis

Muhammad Usman Haider, Ishtiaq Ahmad, Faiza Khan, Hasan Ilyas, Muhammad Furqan, Muhammad Tayyab Tahir, Wasique Mirza, Daniah Rizwan, Ali Mohsin, Abdullah Sohail, …
The American journal of gastroenterology, Vol.121(10S1), pp.S587-S587
10/01/2026
DOI: 10.14309/01.ajg.0001220016.13383.6d

View Online

Abstract

Introduction: Patients with cirrhosis and type 2 diabetes mellitus (T2DM) are at increased risk of hepatic decompensation and mortality. Emerging data suggest sodium-glucose cotransporter-2 (SGLT2) inhibitors may provide benefits beyond glycemic control. We evaluated the association between SGLT2 inhibitor use and liver-related outcomes in patients with cirrhosis and T2DM. Methods: We performed a retrospective cohort study using the TriNetX Global Collaborative Network. Adults with cirrhosis and T2DM receiving dapagliflozin, empagliflozin, or canagliflozin were compared with matched controls receiving furosemide and spironolactone without SGLT2 inhibitor exposure. Patients with prior hepatic decompensation, hepatocellular carcinoma, liver transplantation, advanced chronic kidney disease, dialysis, or renal transplantation were excluded. Propensity score matching (PSM) was performed for demographics, comorbidities, medications, and laboratory variables, yielding 9,937 patients in each cohort. The primary outcome was a 3-year composite of spontaneous bacterial peritonitis (SBP), variceal bleeding, and need for therapeutic paracentesistatus posteritoneal drainage. Secondary outcomes included individual decompensation events, bacteremia, and all-cause mortality. Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Results: After PSM, SGLT2 inhibitor use was associated with a significantly lower risk of the composite hepatic decompensation outcome at 3 years (2.3% vs 3.6%; HR 0.58, 95% CI 0.49–0.69; P < 0.001). Individual analyses demonstrated lower risks of SBP (HR 0.43, 95% CI 0.31–0.58; P < 0.001) and peritoneal drainage/paracentesis-related procedures (HR 0.63, 95% CI 0.52–0.76; P < 0.001). Independent assessment of variceal bleeding was limited by low event counts. SGLT2 inhibitor use was also associated with lower all-cause mortality at 3 years (HR 0.64, 95% CI 0.60–0.67; P < 0.001) and 5 years (HR 0.52, 95% CI 0.48–0.57; P < 0.001). Bacteremia was significantly associated with SGLT2 inhibitor use by odds ratio analysis but did not demonstrate a significant difference on time-to-event analysis. Conclusion: In this large propensity-matched real-world study, SGLT2 inhibitor therapy was associated with significantly lower risks of hepatic decompensation and mortality among patients with cirrhosis and T2DM. These findings support further prospective evaluation of SGLT2 inhibitors as a potential disease-modifying therapy in cirrhosis.
Diabetes Antidiabetics Liver cirrhosis Mortality

Details

Metrics

2 Record Views
Logo image